Allarity Therapeutics Announces Reverse Stock Split of Common Stock
June 28, 2023 11:55 ET
|
Allarity Therapeutics, Inc.
- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 29, 2023 Press ReleaseBOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”),...
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
June 27, 2023 18:16 ET
|
Allarity Therapeutics, Inc.
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
June 20, 2023 16:05 ET
|
Allarity Therapeutics, Inc.
Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
May 30, 2023 06:00 ET
|
Allarity Therapeutics, Inc.
Phase 2 study evaluating the utility of a DRP® companion diagnostic for cisplatin supports its ability to predict drug response in certain breast cancer patients Boston, MA (May 30, 2023) —...
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
April 19, 2023 09:18 ET
|
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
April 11, 2023 07:00 ET
|
Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study...
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
March 28, 2023 06:00 ET
|
Allarity Therapeutics, Inc.
Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipated in H2 2023. Press release BOSTON — March 28,...
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
March 24, 2023 06:00 ET
|
Allarity Therapeutics, Inc.
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”),...
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
March 20, 2023 06:00 ET
|
Allarity Therapeutics, Inc.
Company anticipates that the combination of pan-TKI dovitinib and PARP inhibitor stenoparib may generate synergistic anti-cancer activity Program initiation marks key milestone in Allarity’s...
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
January 20, 2023 16:01 ET
|
Allarity Therapeutics, Inc.
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together...